tbuckley/cabot-search huggingface dataset:
The Body as Poetry
Authors: Rafael Campo
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tools and toys beyond RANO 2.0: digital flipbooks to monitor brain tumor growth dynamics?
Authors: Emilie Le Rhun, Michael Weller
Journal: Neuro-Oncology (2024)

Journal Article Accepted manuscript Tools and toys beyond RANO 2.0: digital flipbooks to monitor brain tumor growth dynamics? Get access Emilie Le Rhun, Emilie Le Rhun Department of Medical Oncology and Hematology, Brain Tumor Center & Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland https://orcid.org/0000-0002-9408-3278 Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael Weller Michael Weller Department of Neurology, Brain Tumor Center & Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland Coressponding: michael.weller@usz.ch https://orcid.org/0000-0002-1748-174X Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, noae141, https://doi.org/10.1093/neuonc/noae141 Published: 31 July 2024 Article history Received: 24 July 2024 Published: 31 July 2024
NKT cells promote Th1 immune bias to dengue virus that governs long term protective antibody dynamics
Authors: Youngjoo Choi, Wilfried A.A. Saron, Aled O’Neill, Manouri Senanayake, Annelies Wilder-Smith, Abhay P.S. Rathore, Ashley L. St. John
Journal: Journal of Clinical Investigation (2024)

NKT cells are innate-like T cells, recruited to the skin during viral infection, yet their contributions to long-term immune memory to viruses are unclear. We identified granzyme K, a product made by cytotoxic cells including NKT cells, as linked to induction of Th1-associated antibodies during primary dengue virus (DENV) infection in humans. We examined the role of NKT cells in vivo using DENV-infected mice lacking CD1d-dependent (CD1ddep) NKT cells. In CD1d-KO mice, Th1-polarized immunity and infection resolution were impaired, which was dependent on intrinsic NKT cell production of IFN-γ, since it was restored by adoptive transfer of WT but not IFN-γ-KO NKT cells. Furthermore, NKT cell deficiency triggered immune bias, resulting in higher levels of Th2-associated IgG1 than Th1-associated IgG2a, which failed to protect against a homologous DENV rechallenge and promoted antibody-dependent enhanced disease during secondary heterologous infections. Similarly, Th2 immunity, typified by a higher IgG4/IgG3 ratio, was associated with worsened human disease severity during secondary infections. Thus, CD1ddep NKT cells establish Th1 polarity during the early innate response to DENV, which promotes infection resolution, memory formation, and long-term protection from secondary homologous and heterologous infections in mice, with consistent associations observed in humans. These observations illustrate how early innate immune responses during primary infections can influence secondary infection outcomes.
Zonation and ligand and dose dependence of sphingosine 1-phosphate receptor-1 signalling in blood and lymphatic vasculature
Authors: Ilaria Del Gaudio, Anja Nitzsche, Kevin Boyé, Philippe Bonnin, Mathilde Poulet, Toan Q Nguyen, Ludovic Couty, Hoa T T Ha, Dat T Nguyen, Amaury Cazenave-Gassiot, Khaoula Ben Alaya, Patrice Thérond, Jerold Chun, Markus R Wenk, Richard L Proia, Daniel Henrion, Long N Nguyen, Anne Eichmann, Eric Camerer
Journal: Cardiovascular Research (2024)

Abstract Aims Circulating levels of sphingosine 1-phosphate (S1P), an HDL-associated ligand for the endothelial cell (EC) protective S1P receptor-1 (S1PR1), are reduced in disease states associated with endothelial dysfunction. Yet, as S1PR1 has high affinity for S1P and can be activated by ligand-independent mechanisms and EC autonomous S1P production, it is unclear if relative reductions in circulating S1P can cause endothelial dysfunction. It is also unclear how EC S1PR1 insufficiency, whether induced by deficiency in circulating ligand or by S1PR1-directed immunosuppressive therapy, affects different vascular subsets. Methods and results We here fine map the zonation of S1PR1 signalling in the murine blood and lymphatic vasculature, superimpose cell-type–specific and relative deficiencies in S1P production to define ligand source and dose dependence, and correlate receptor engagement to essential functions. In naïve blood vessels, despite broad expression, EC S1PR1 engagement was restricted to resistance-size arteries, lung capillaries, and a subset of high-endothelial venules (HEVs). Similar zonation was observed for albumin extravasation in EC S1PR1-deficient mice, and brain extravasation was reproduced with arterial EC-selective S1pr1 deletion. In lymphatic ECs, S1PR1 engagement was high in collecting vessels and lymph nodes and low in blind-ended capillaries that drain tissue fluids. While EC S1P production sustained S1PR1 signalling in lymphatics and HEV, haematopoietic cells provided ∼90% of plasma S1P and sustained signalling in resistance arteries and lung capillaries. S1PR1 signalling and endothelial function were both surprisingly sensitive to reductions in plasma S1P with apparent saturation around 50% of normal levels. S1PR1 engagement did not depend on sex or age but modestly increased in arteries in hypertension and diabetes. Sphingosine kinase (Sphk)-2 deficiency also increased S1PR1 engagement selectively in arteries, which could be attributed to Sphk1-dependent S1P release from perivascular macrophages. Conclusion This study highlights vessel subtype-specific S1PR1 functions and mechanisms of engagement and supports the relevance of S1P as circulating biomarker for endothelial function.
Mainstreaming genetic testing in dermatology in the United Kingdom
Authors: Cathal O’Connor, Lauren Passby, Carly Fields, John McGrath, Edel A O’Toole, Neil Rajan
Journal: British Journal of Dermatology (2024)

Genetic testing is being increasingly integrated into mainstream healthcare and is one of the latest advances dermatologists can offer to certain patients to improve their care. Developments in genetic skin disease continue to progress at pace, and dermatologists are well placed to phenotype and test for rare skin diseases in the clinic. Patients who have a molecular genetic diagnosis will inform rare disease research, natural history studies and clinical trials. By using new technologies, increasing awareness and improving access to care, we can help ensure that patients with rare diseases receive the support and treatment they deserve.
Neuroimmune circuits in the plaque and bone marrow regulate atherosclerosis
Authors: Teresa Gerhardt, Pacific Huynh, Cameron S McAlpine
Journal: Cardiovascular Research (2024)

Atherosclerosis remains the leading cause of death globally. Although its focal pathology is atheroma that develops in arterial walls, atherosclerosis is a systemic disease involving contributions by many organs and tissues. It is now established that the immune system causally contributes to all phases of atherosclerosis. Recent and emerging evidence positions the nervous system as a key modulator of inflammatory processes that underly atherosclerosis. This neuro-immune crosstalk, we are learning, is bidirectional, and immune regulated afferent signaling is becoming increasingly recognized in atherosclerosis. Here, we summarize data and concepts that link the immune and nervous systems in atherosclerosis by focusing on two important sites, the arterial vessel and the bone marrow.
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (<scp>HFA</scp>) of the <scp>ESC</scp> and the <scp>ESC</scp> Council of Cardio‐Oncology
Authors: Carlo Gabriele Tocchetti, Dimitrios Farmakis, Yvonne Koop, Maria Sol Andres, Liam S. Couch, Luigi Formisano, Fortunato Ciardiello, Fabrizio Pane, Lewis Au, Max Emmerich, Chris Plummer, Geeta Gulati, Sivatharshini Ramalingam, Daniela Cardinale, Christine Brezden‐Masley, Zaza Iakobishvili, Paaladinesh Thavendiranathan, Ciro Santoro, Jutta Bergler‐Klein, Kalliopi Keramida, Rudolf A. de Boer, Christoph Maack, Esther Lutgens, Tienush Rassaf, Michael G. Fradley, Javid Moslehi, Eric H. Yang, Gilles De Keulenaer, Pietro Ameri, Jeroen Bax, Tomas G. Neilan, Joerg Herrmann, Amam C. Mbakwem, Mariana Mirabel, Hadi Skouri, Emilio Hirsch, Alain Cohen‐Solal, Aaron L. Sverdlov, Peter van der Meer, Riccardo Asteggiano, Ana Barac, Bonnie Ky, Daniel Lenihan, Susan Dent, Petar Seferovic, Andrew J.S. Coats, Marco Metra, Giuseppe Rosano, Thomas Suter, Teresa Lopez‐Fernandez, Alexander R. Lyon
Journal: European Journal of Heart Failure (2024)
Dendritic Cell Plasticity, Radiation, and Newton's Third Law
Authors: Pawel Kalinski, Shipra Gandhi, Kathleen M. Kokolus
Journal: Clinical Cancer Research (2024)

Regulatory T cells protect damaged tissues but can undermine the effects of cancer treatments, including radiotherapy (RTx). Intratumoral immunostimulatory dendritic cells (type 1 conventional dendritic cells) respond to RTx with the production of regulatory T cell-attracting MDC/CCL22, undermining RTx effects. That effect can be reversed by EGFR-targeted IFNα, highlighting cDC1 plasticity and relevance as therapeutic targets. See related article by Bugno et al., p. 4450.
First-Line Tyrosine Kinase Inhibitors in Soft-Tissue Sarcomas: A Role for Anlotinib?
Authors: Andrea Napolitano, Paul H. Huang, Robin L. Jones
Journal: Clinical Cancer Research (2024)

The optimal medical treatment of chemotherapy-ineligible patients affected by advanced soft-tissue sarcomas is unclear. In this population, tyrosine kinase inhibitors represent an appealing alternative treatment strategy. First-line use of the tyrosine kinase inhibitor anlotinib in chemotherapy-ineligible patients with soft-tissue sarcoma showed promising activity across multiple histologies. See related article by Li et al., p. 4310.
Elacestrant in ER+, HER2– MBC with <i>ESR1</i>-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups
Authors: Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz, Phillipe Aftimos, Joyce O’Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1-mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER+, HER2− metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 (&amp;lt;3 metastatic sites), 10.8 versus 1.8 (≥3 metastatic sites), 5.5 versus 1.9 (PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 (ESR1D538G-mutated tumors), and 9.0 versus 1.9 (ESR1Y537S/N-mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER+, HER2−, ESR1-mutated tumors.
POS0594 NEW INSIGHTS INTO EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS SUBTYPES THROUGH SEROLOGIC BIOMARKER PROFILING – RESULTS FROM THE SCANDRA PROJECT
Authors: J. Rojas-Restrepo, I. Gehring, N. Ghasemzadeh, L. Christiansson, L. Mathsson-Alm, E. A. Haavardsholm, T. K. Kvien, M. D. Mjaavatten, H. Westerlind, H. B. Hammer, J. Askling
Journal: Annals of the Rheumatic Diseases (2024)
POS0656 INDIVIDUAL CV RISK ESTIMATION TO EVALUATE ELIGIBILITY FOR JAKi THERAPY: DATA FROM THE CARDIOVASCULAR OBESITY AND RHEUMATIC DISEASES STUDY GROUP OF THE ITALIAN SOCIETY OF RHEUMATOLOGY
Authors: F. Cacciapaglia, F. Atzeni, E. Bartoloni, E. Gremese, A. Manfredi, M. Piga, G. Sakellariou, F. R. Spinelli, O. Viapiana, G. L. Erre
Journal: Annals of the Rheumatic Diseases (2024)
OP0007 SUBCUTANEOUS ABATACEPT VS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN ADULTS WITH EARLY, DUAL SEROPOSITIVE RHEUMATOID ARTHRITIS, POSITIVE FOR THE SHARED EPITOPE HLA CLASS II RISK ALLELES, AND AN INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE PHASE 3 AMPLIFIED TRIAL
Authors: M. A. Maldonado, P. Emery, M. E. Weinblatt, V. Bykerk, A. Cope, G. R. Burmester, Y. Tanaka, G. Citera, P. Nash, Q. Dornic, S. Kelly
Journal: Annals of the Rheumatic Diseases (2024)
POS0658 LONG-TERM EFFICACY OF FILGOTINIB MONOTHERAPY AND COMBINATION THERAPY: INTERIM RESULTS FROM A POST HOC ANALYSIS OF THE FINCH 4 STUDY
Authors: M. Buch, P. Verschueren, R. F. Caporali, T. Huizinga, E. V. Ekoka Omoruyi, D. De Vries, J. Ritsema, F. De Leonardis, D. Aletaha
Journal: Annals of the Rheumatic Diseases (2024)
POS0660 DRUG RETENTION OF TNFi BIOSIMILARS AND BIO-ORIGINALS IN DAILY RHEUMATOLOGY CARE IN GERMANY: INSIGHTS FROM THE RABBIT REGISTER
Authors: F. Frederking, M. Kramer, J. Kekow, M. Schmalzing, H. Fricke-Wagner, A. Strangfeld
Journal: Annals of the Rheumatic Diseases (2024)
AB0283 MALE OSTEOPOROSIS: EPIDEMIOLOGICAL, CLINICAL AND ETIOLOGICAL PROFILE
Authors: M. Kamoun, Z. Gassara, A. Feki, Y. Tekaya, S. Ben Jmeaa, M. Ezzeddine, R. Akrout, M. H. Kallel, H. Fourati, S. Baklouti
Journal: Annals of the Rheumatic Diseases (2024)
AB0275 EXPLORING THE VALIDITY AND RELIABILITY OF THE JUVENILE ARTHRITIS QUALITY OF LIFE QUESTIONNAIRE IN PEDIATRIC PATIENTS DIAGNOSED WITH JUVENILE IDIOPATHIC ARTHRITIS: A TURKISH ADAPTATION STUDY
Authors: Y. Doğan, N. B. Karaca, S. Buran, O. Tüfekçi, E. N. Atabey Gerlegiz, E. Aliyev, Y. Bayindir, Y. Bilginer, E. Ünal, S. Ozen
Journal: Annals of the Rheumatic Diseases (2024)
OP0043 THE EFFECTIVENESS OF RITUXIMAB IN THE REAL-WORLD TREATMENT OF NEUROPSYCHIATRIC SLE: RESULTS FROM THE BRITISH ILES LUPUS ASSESSMENT GROUP BIOLOGICS REGISTER (BILAG-BR)
Authors: M. Rodziewicz, S. Dyball, T. David, E. Sutton, B. Parker, I. N. Bruce
Journal: Annals of the Rheumatic Diseases (2024)
AB0282 EVALUATION OF BONE DENSITY AND FRACTURE RISK AFTER DISCONTINUATION OF A BISPHOSPHONATE THERAPEUTIC SEQUENCE IN A RHEUMATOLOGY DEPARTMENT
Authors: C. Ben Ammar, R. Fakhfakh, N. El Amri, D. Khalifa, C. Daldoul, H. Hachfi, K. Baccouche, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2024)
A manifesto on improving cancer care in conflict-impacted populations
Authors: Tedros Adhanom Ghebreyesus, Dina Mired, Richard Sullivan, Alexandra Mueller, Andreas Charalambous, Arman Kacharian, Christos Tsagkaris, Enrique Soto-Perez-de-Celis, Henrik Grigoryan, Julie Gralow, Andre Ilbawi, Khaled Ghanem, Layth Mula-Hussain, Bente Mikkelsen, Mulugeta Yimer, Nazik Hammad, Stella Arakelyan, Tezer Kutluk, Zeena Salman, Mark Lawler, Gevorg Tamamyan, Maria V Babak, Jemma Arakelyan
Journal: The Lancet (2024)
AB0532 SERUM BIOMARKERS OF PULMONARY DAMAGE AND RISK FOR PROGRESSION OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
Authors: J. A. Sparks, S. H. Chang, K. Hayashi, G. Mcdermott, M. L. Paudel, Y. J. Ha, J. S. Lee, M. U. Kim, C. H. Park, J. W. Kim, J. W. Ha, S. W. Chung, S. W. Lee, E. H. Kang, Y. A. Lee, Y. Park, J. Y. Choe, E. Y. Lee
Journal: Annals of the Rheumatic Diseases (2024)
AB0529 JAK-INHIBITORS PROMOTE INSULIN SENSITIVITY AND ENHANCE IMMUNOSUPPRESSIVE EFFECT OF INSULIN ON CD4+ T CELLS OF PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: M. Erlandsson, M. Tuameh, V. Chandrasekaran, K. M. E. Andersson, M. I. Bokarewa
Journal: Annals of the Rheumatic Diseases (2024)
AB0569 PATIENT-REPORTED OUTCOMES (PROs), DISEASE ACTIVITY AND SAFETY IN 1,177 PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH FILGOTINIB FOR UP TO 18 MONTHS: INTERIM RESULTS FROM FILOSOPHY AND PARROTFISH
Authors: J. Avouac, G. R. Burmester, R. F. Caporali, T. P. A. Debray, F. De Leonardis, J. Galloway, N. Betteridge, K. Bevers, S. Romero-Yuste, M. Zignani, P. Verschueren
Journal: Annals of the Rheumatic Diseases (2024)
AB0561 SARCOPENIA IN RHEUMATOID ARTHRITIS: A LONG-TERM PROSPECTIVE STUDY
Authors: R. Cavalheiro Do Espirito Santo, D. Moraes, L. Denardi Dória, L. Dos Santos, S. Pilotti, A. L. Mallmann, V. Hax, T. Muniz Fighra, P. M. Spritzer, R. Machado Xavier
Journal: Annals of the Rheumatic Diseases (2024)
AB0525 EARLY RESPONDERS TO REMISSION-INDUCTION TREATMENT WITH METHOTREXATE AND BRIDGING GLUCOCORTICOIDS REPORT LOWER RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAID) OVER 2 YEARS: SECONDARY ANALYSIS OF THE CARERA2020 TRIAL
Authors: M. Doumen, D. Bertrand, J. Joly, E. De Meyst, S. Pazmino, R. Westhovens, P. Verschueren
Journal: Annals of the Rheumatic Diseases (2024)
AB0562 THE EFFECTS OF TOFACITINIB IN SIMULTANEOUSLY IMPROVING GLYCAEMIC PARAMETERS AND INFLAMMATORY MARKERS IN RHEUMATOID ARTHRITIS PATIENTS WITH COMORBID TYPE 2 DIABETES. A PROOF-OF-CONCEPT, OPEN, PROSPECTIVE, CLINICAL STUDY
Authors: P. Ruscitti, C. Di Muzio, I. Di Cola, A. Shariat Panahi, F. Sensini, F. Ursini, A. Iagnocco, R. Giacomelli, P. Cipriani
Journal: Annals of the Rheumatic Diseases (2024)
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study
Authors: Leopoldo Pérez de Isla, Antonio J Vallejo-Vaz, Gerald F Watts, Ovidio Muñiz-Grijalvo, Rodrigo Alonso, Jose L Diaz-Diaz, Raquel Arroyo-Olivares, Rocio Aguado, Rosa Argueso, Marta Mauri, Manuel J Romero, Pilar Álvarez-Baños, Dolores Mañas, José María Cepeda, Pablo Gonzalez-Bustos, Marta Casañas, Alfredo Michan, Juan F Sánchez Muñoz-Torrero, Ceferino Faedo, Miguel A Barba, Marta Dieguez, Raimundo de Andrés, Antonio M Hernandez, Aurora Gonzalez-Estrada, Teresa Padró, Francisco Fuentes, Lina Badimon, Pedro Mata
Journal: The Lancet Diabetes & Endocrinology (2024)
Progress and Challenges in the Field of Snakebite Envenoming Therapeutics
Authors: José María Gutiérrez, Nicholas R. Casewell, Andreas H. Laustsen
Journal: The Annual Review of Pharmacology and Toxicology (2024)

Snakebite envenoming kills and maims hundreds of thousands of people every year, especially in the rural settings of tropical regions. Envenomings are still treated with animal-derived antivenoms, which have prevented many lives from being lost but which are also medicines in need of innovation. Strides are being made to improve envenoming therapies, with promising efforts made toward optimizing manufacturing and quality aspects of existing antivenoms, accelerating research and development of recombinant antivenoms based on monoclonal antibodies, and repurposing of small-molecule inhibitors that block key toxins. Here, we review the most recent advances in these fields and discuss therapeutic opportunities and limitations for different snakebite treatment modalities. Finally, we discuss challenges related to preclinical and clinical evaluation, regulatory pathways, large-scale manufacture, and distribution and access that need to be addressed to fulfill the goals of the World Health Organization's global strategy to prevent and control snakebite envenoming.
Prospects for Disease Slowing in Parkinson Disease
Authors: Elisa Menozzi, Anthony H.V. Schapira
Journal: The Annual Review of Pharmacology and Toxicology (2024)

The increasing prevalence of Parkinson disease (PD) highlights the need to develop interventions aimed at slowing or halting its progression. As a result of sophisticated disease modeling in preclinical studies, and refinement of specific clinical/genetic/pathological profiles, our understanding of PD pathogenesis has grown over the years, leading to the identification of several targets for disease modification. This has translated to the development of targeted therapies, many of which have entered clinical trials. Nonetheless, up until now, none of these treatments have satisfactorily shown disease-modifying effects in PD. In this review, we present the most up-to-date disease-modifying pharmacological interventions in the clinical trial pipeline for PD. We focus on agents that have reached more advanced stages of clinical trials testing, highlighting both positive and negative results, and critically reflect on strengths, weaknesses, and challenges of current disease-modifying therapeutic avenues in PD.
Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial
Authors: Ahmed H Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Lamis Ahmed Fahal, Abubakar Ahmed Mohamed, El Semani Widaa Mohamedelamin, Mustafa El Nour Bahar, Hadil Yassir Attalla, Emmanuel Edwar Siddig, Najwa A Mhmoud, Ahmed Mudawi Musa, Wendy W J van de Sande, Bruno Scherrer, Peelen Oyieko, Thaddaeus W Egondi, Kevin O Onyango, Katsura Hata, Wan-Yu Chu, Thomas P C Dorlo, Roger J Brüggemann, Borna A Nyaoke, Nathalie Strub-Wourgaft, Eduard E Zijlstra
Journal: The Lancet Infectious Diseases (2024)